JPRN-jRCTs031200144进行中（未招募）2 期
Comparison of colestimide /elovixibat combination therapy versus colestimide /placebo combintion in NASH patients with dyslipidemia: a multicenter, double-blind, randomized controlled study(NECST) - NECST
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 85age old（—）
- 性别
- All
入选标准
- •1) Patients between the ages of 20 and 85 years old at the time of obtaining consent
- •2) Patients whose liver biopsy within 16 weeks prior to enrollment meet the following
- •Fibrosis stage F1 to F3 and NAFLD activity score (NAS) of 4 or more (1 point or more for each category) on the NASH Clinical Research Network (CRN) criteria
- •1. steatosis (0-3 points)
- •2. ballooning (0-2 points)
- •3. lobular inflammation (0-3 points)
- •3) Patients who meet either (1) or (2) below within 12 weeks prior to enrollment
- •(1) Patients who meet any of the following values
- •1. Triglycerides (TG)150 mg/dL
- •2. HDL cholesterol (HDL-C)<40 mg/dL
- •3. LDL cholesterol (LDL-C)>=120 mg/dL
- •(2) Patients diagnosed with dyslipidemia and undergoing drug treatment
- •4) Patients whose written consent to participate in the study has been obtained
- •5) Patients with a stable diet and physical activity during the study
- •At allocation Dose initiation criteria
- •1) Patients whose liver biopsy within 16 weeks prior to enrollment meet the following
- •Fibrosis stage F1 to F3 and NAFLD activity score (NAS) of 4 or more (1 point or more for each category) on the NASH Clinical Research Network (CRN) criteria
- •1. steatosis (0-3 points)
- •2. ballooning (0-2 points)
- •3. lobular inflammation (0-3 points)
- •2) ALT greater than 43 IU/L for males and 24 IU/L for females within 12 weeks prior to the start of treatment
- •3) ALT=<300IU/L or AST=<300IU/L within 12 weeks prior to the start of treatment
- •4) Body mass index (BMI)>=22 kg/m2 within 12 weeks prior to the start of treatment
- •5) Patients with no weight change of 10% or more within 12 weeks before the start of administration
- •6) Patients with total bilirubin=<3.0 mg/dl within 12 weeks prior to the start of treatment ( except for Gilberts syndrome)
- •7) In case the patient had been taking SGLT2 inhibitors, GLP-1 agonists, thiazolidinediones, or vitamin E within 24 weeks prior to the start of treatment, the patient must be on the same drug and at the same dose.(Patients who have started, discontinued, changed drugs, or changed doses are not eligible.)
排除标准
- •1) Patients with a evidence of acute or chronic liver disease other than NASH
- •(1) Hepatitis B (excluding past infection) or C (excluding post-SVR)
- •(2) Patients with autoimmune hepatitis
- •(3) Patients with primary cholangitis, primary sclerosing cholangitis, Wilson's disease, alpha1-antitrypsin deficiency, hemochromatosis or iron overload, drug or alcoholic liver disease, or bile duct obstruction.
- •(4) Patients with suspected or confirmed diagnosis of hepatocellular carcinoma
- •2) Patients with an average alcohol intake of 30 g of ethanol equivalent per day or more for males and 20 g or more for females (more than 12 weeks) in the year before consent was obtained.
- •3) Patients who are pregnant, lactating, women of childbearing potential, or who cannot consent to use contraception while participating in the study.
- •4) Patients with concomitant malignancies; Patients who have undergone radical surgery or completed chemotherapy are eligible for enrollment.
- •5) Patients with liver cirrhosis
- •6) Patients with findings of portal hypertension (platelets <80,000/uL, varices, ascites, hepatic encephalopathy, splenomegaly)
- •7) Patients who changed the dose of SGLT2 inhibitor, GLP-1 agonist, thiazolidine or vitamin E within 24 weeks prior to enrollment.
- •8) Patients on insulin therapy
- •9) Patients with a history of drug abuse
- •10) Patients with serious renal or cardiac disease
- •11) Patients with a history of allergy to this study drug
- •12) Patients who participate in another clinical research within 4 weeks prior to participation in this study, except for observational studies.
- •13) Other patients who are deemed inappropriate for this study by the investigators
研究者
相似试验
已完成
2 期
Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver DiseaseJPRN-jRCT2080225028Takaomi Kessoku100
进行中（未招募）
1 期
AMedDRA version: 17.0Level: PTClassification code 10040070Term: Septic shockSystem Organ Class: 10021881 - Infections and infestationsSeptic shockEUCTR2014-002440-41-DKRigshospitalet, Capital Region Bloodbank 2034, Section for Transfusion Medicine
已完成
不适用
Effectiveness of Elobixibat and Linaclotide in neurogenic bowel dysfunction due to spinal cord injuryJPRN-UMIN000035923ational Hospital Organization Murayama Medical Center80
已完成
2 期
Co-administration of Iloprost and Eptifibatide in Septic Shock PatientsSeptic ShockNCT02204852Sisse R. Ostrowski, MD PhD DMSc18
进行中（未招募）
1 期
Efficacy and Safety of Edoxaban and or Colchicine for patients with SARS-CoV-2 infection managed in the out of hospital setting (COVID 19)Patients with laboratory confirmed SARS-CoV-2 infection (under RT PCR) who are managed at home or in another out-of-hospital setting.MedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862EUCTR2020-002234-32-ITINSEL GRUPPE AG, BERN UNIVERSITY HOSPITAL, DEPARTMENT OF CARDIOLOGY420